Clinical proteomics of myeloid leukemia

Genome Medicine

Volumn 2, Issue 6, 2010, Pages

  Hjelle, Sigrun M ^a   Forthun, Rakel B ^a   Haaland, Ingvild ^a   Reikvam, Håkon ^a   Sjøholt, Gry ^c   Bruserud, Øystein ^a,b   Gjertsen, Bjørn T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c BERGEN UNIVERSITY COLLEGE   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID;

BONE MARROW CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; ISOTOPE LABELING; MYELOID LEUKEMIA; NANOFLUIDICS; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 78751700767     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm162     Document Type: Review

References (67)

1. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009, 21:594-600. 10.1097/CCO.0b013e32833118fd, 19684517.
2. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009, 636-642.
3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061. 10.1038/leu.2009.38, 19282833.
4. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Kocher T, Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063. 10.1182/blood-2007-07-102061, 17720881.
5. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010, 6:291-299. 10.1038/nchembio.332, 20190765.
6. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136. 10.1182/blood-2009-10-246363, 20008298.
7. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293. 10.1038/243290a0, 4126434.
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037. 10.1056/NEJM200104053441401, 11287972.
9. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009, 453-460.
10. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907. 10.1016/S0140-6736(06)69780-8, 17126723.
11. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008, 1-11.
12. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918. 10.1056/NEJMoa074306, 18450602.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458. 10.1111/j.1365-2141.1976.tb03563.x, 188440.
14. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515. 10.1182/blood-2007-07-102798, 18299451.
15. Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Oyan AM, Kalland KH, Gjertsen BT. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007, 92:332-341. 10.3324/haematol.10148, 17339182.
16. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628. 10.1056/NEJMoa040465, 15084694.
17. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008, 22:1335-1342. 10.1038/leu.2008.162, 18548091.
18. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010, 16:2246-2256. 10.1158/1078-0432.CCR-09-2112, 20371679.
19. Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009, 113:1749-1755. 10.1182/blood-2008-04-152157, 2647674, 19075190.
20. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 2009, 15:566-571. 10.1038/nm.1903, 19363496.
21. O'Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J, Gentalen E, Glazer M, Gossett J, Hacker K, Kirby C, Knittle J, Loder R, Mastroieni C, Maclaren M, Mills T, Nguyen U, Parker N, Rice A, Roach D, Suich D, Voehringer D, Voss K, Yang J, Yang T, Vander Horn PB. Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA 2006, 103:16153-16158. 10.1073/pnas.0607973103, 1618307, 17053065.
22. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 2008, 25:1469-1483. 10.1007/s11095-008-9532-4, 18219561.
23. Onisko B, Dynin I, Requena JR, Silva CJ, Erickson M, Carter JM. Mass spectrometric detection of attomole amounts of the prion protein by nanoLC/MS/MS. J Am Soc Mass Spectrom 2007, 18:1070-1079. 10.1016/j.jasms.2007.03.009, 17446085.
24. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641. 10.1038/nbt.1546, 2855883, 19561596.
25. Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35:265-273. 10.1016/j.ymeth.2004.08.018, 15722223.
26. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386. 10.1074/mcp.M200025-MCP200, 12118079.
27. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fassler R, Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008, 134:353-364. 10.1016/j.cell.2008.05.033, 18662549.
28. Xiong L, Wang Y. Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment. J Proteome Res 2010, 9:1129-1137. 10.1021/pr9011359, 20050688.
29. Pan C, Olsen JV, Daub H, Mann M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 2009, 8:2796-2808. 10.1074/mcp.M900285-MCP200, 2816010, 19651622.
30. Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 2006, 6:4554-4564. 10.1002/pmic.200600109, 16858728.
31. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H. Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 2009, 8:1751-1764. 10.1074/mcp.M800588-MCP200, 19369195.
32. Oveland E, Gjertsen BT, Wergeland L, Selheim F, Fladmark KE, Hovland R. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leuk Res 2009, 33:276-287.
33. Yocum AK, Busch CM, Felix CA, Blair IA. Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4;11) translocations. J Proteome Res 2006, 5:2743-2753. 10.1021/pr060235v, 17022645.
34. Gausdal G, Gjertsen BT, Fladmark KE, Demol H, Vandekerckhove J, Doskeland SO. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia 2004, 18:1989-1996. 10.1038/sj.leu.2403508, 15483679.
35. Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C, Bruserud O, Gevaert K, Vandekerckhove J, Doskeland SO. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood 2008, 111:2866-2877. 10.1182/blood-2007-07-103242, 18182573.
36. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3:36-44. 10.1002/pmic.200390006, 12548632.
37. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077. 10.1002/elps.1150181133, 9420172.
38. Agarwal NK, Mueller GA, Mueller C, Streich JH, Asif AR, Dihazi H. Expression proteomics of acute promyelocytic leukaemia cells treated with methotrexate. Biochim Biophys Acta 2010, 1804:918-928.
39. Shen SH, Gu LJ, Liu PQ, Ye X, Chang WS, Li BS. Comparative proteomic analysis of differentially expressed proteins between K562 and K562/ADM cells. Chin Med J (Engl) 2008, 121:463-468.
40. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999. 10.1038/13690, 10504701.
41. Hansen KC, Schmitt-Ulms G, Chalkley RJ, Hirsch J, Baldwin MA, Burlingame AL. Mass spectrometric analysis of protein mixtures at low levels using cleavable 13C-isotope-coded affinity tag and multidimensional chromatography. Mol Cell Proteomics 2003, 2:299-314.
42. Oda Y, Owa T, Sato T, Boucher B, Daniels S, Yamanaka H, Shinohara Y, Yokoi A, Kuromitsu J, Nagasu T. Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 2003, 75:2159-2165. 10.1021/ac026196y, 12720356.
43. Shiio Y, Aebersold R. Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc 2006, 1:139-145. 10.1038/nprot.2006.22, 17406225.
44. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 2001, 19:946-951. 10.1038/nbt1001-946, 1444949, 11581660.
45. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169. 10.1074/mcp.M400129-MCP200, 15385600.
46. Griffiths SD, Burthem J, Unwin RD, Holyoake TL, Melo JV, Lucas GS, Whetton AD. The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol 2007, 36:81-89. 10.1007/s12033-007-0005-5, 17914187.
47. Zhang Y, Askenazi M, Jiang J, Luckey CJ, Griffin JD, Marto JA. A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. Mol Cell Proteomics 2010, 9:780-790. 10.1074/mcp.M900452-MCP200, 20019052.
48. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta 2005, 357:180-183. 10.1016/j.cccn.2005.03.024, 15921671.
49. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989. 10.1038/sj.onc.1204265, 11360182.
50. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007, 6:1414-1424. 10.1158/1535-7163.MCT-06-0678, 17431120.
51. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006, 5:2512-2521. 10.1158/1535-7163.MCT-06-0334, 17041095.
52. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010, 16:1865-1874. 10.1158/1078-0432.CCR-09-2551, 20215543.
53. Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res 2009, 69:2471-2478. 10.1158/0008-5472.CAN-08-3404, 19258499.
54. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113:154-164. 10.1182/blood-2007-10-119438, 18840713.
55. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131. 10.1182/blood-2002-06-1714, 12424199.
56. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia 2010, 24:33-43. 10.1038/leu.2009.212, 19946262.
57. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003, 100:6940-6945. 10.1073/pnas.0832254100, 165809, 12771378.
58. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222. 10.1038/msb.2008.61, 2583086, 18854821.
59. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228. 10.1016/j.cell.2004.06.028, 15260991.
60. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008, 14:335-343. 10.1016/j.ccr.2008.08.014, 2647559, 18835035.
61. Tanner SD, Bandura DR, Ornatsky O, Baranov VI, Nitz M, Winnik MA. Flow cytometer with mass spectrometer detection for massively multiplexed single-cell biomarker assay. Pure Appl Chem 2008, 80:2627-2641.
62. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009, 81:6813-6822. 10.1021/ac901049w, 19601617.
63. Weerkamp F, Dekking E, Ng YY, van der Velden VH, Wai H, Bottcher S, Bruggemann M, van der Sluijs AJ, Koning A, Boeckx N, Van Poecke N, Lucio P, Mendonca A, Sedek L, Szczepanski T, Kalina T, Kovac M, Hoogeveen PG, Flores-Montero J, Orfao A, Macintyre E, Lhermitte L, Chen R, Brouwer-De Cock KA, van der Linden A, Noordijk AL, Comans-Bitter WM, Staal FJ, van Dongen JJ. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009, 23:1106-1117. 10.1038/leu.2009.93, 19387467.
64. La Rosee P, Holm-Eriksen S, Konig H, Hartel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 2008, 93:765-769. 10.3324/haematol.12186, 18367481.
65. Soldin SJ, Soldin OP. Steroid hormone analysis by tandem mass spectrometry. Clin Chem 2009, 55:1061-1066. 10.1373/clinchem.2007.100008, 19325015.
66. Ueland PM, Midttun O, Windelberg A, Svardal A, Skalevik R, Hustad S. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry. Clin Chem Lab Med 2007, 45:1737-1745. 10.1515/CCLM.2007.339, 17963453.
67. Findeisen P, Neumaier M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev Proteomics 2009, 6:457-459. 10.1586/epr.09.67, 19811067.